These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30447542)

  • 1. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians.
    Schulman KA; Dabora M
    Am Heart J; 2018 Dec; 206():113-122. PubMed ID: 30447542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impact.
    Weinstein EP; Schulman K
    Am Heart J; 2020 Sep; 227():107-110. PubMed ID: 32730906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in PBM Business Practices in 2019: True Innovation or More of the Same?
    Motheral BR; Fairman KA
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1325-1333. PubMed ID: 32869706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.
    Van Nuys K; Ribero R; Ryan M; Sood N
    JAMA Health Forum; 2021 Nov; 2(11):e213409. PubMed ID: 35977268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy.
    Mattingly TJ; Hyman DA; Bai G
    JAMA Health Forum; 2023 Nov; 4(11):e233804. PubMed ID: 37921745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
    Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
    Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
    Kakani P; Chernew M; Chandra A
    J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remember the MaineRx.
    Kemp R
    Appl Health Econ Health Policy; 2014 Feb; 12(1):1-5. PubMed ID: 24420789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007-20.
    Mallatt J; Dunn A; Fernando L
    Health Aff (Millwood); 2024 Sep; 43(9):1284-1289. PubMed ID: 39226496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primer on brand-name prescription drug reimbursement in the United States.
    Hernandez I; Hung A
    J Manag Care Spec Pharm; 2024 Jan; 30(1):99-106. PubMed ID: 38153864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing High Drug Prices by Reforming Pharmacy Benefit Managers.
    Rome BN
    J Law Med Ethics; 2023; 51(S2):46-51. PubMed ID: 38433673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Price differentiation and transparency in the global pharmaceutical marketplace.
    Ridley DB
    Pharmacoeconomics; 2005; 23(7):651-8. PubMed ID: 15987224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rebates and spreads: pharmacy benefit management practices and corporate citizenship.
    Rentmeester CA; Garis RI
    J Health Polit Policy Law; 2008 Oct; 33(5):943-63; discussion 965-978. PubMed ID: 18818428
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Robinson JC
    J Law Med Ethics; 2023; 51(S2):52-54. PubMed ID: 38433678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
    Bergman MA; Granlund D; Rudholm N
    Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.